[1]
Kiss S,Gede N,Soós A,Hegyi P,Nagy B,Imrei M,Czibere B,Farkas N,Hanák L,Szakács Z,Eröss B,Alizadeh H, Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: A network meta-analysis. Critical reviews in oncology/hematology. 2021 Dec;
[PubMed PMID: 34673218]
Level 1 (high-level) evidence
[2]
Blommestein HM,van Beurden-Tan CHY,Franken MG,Uyl-de Groot CA,Sonneveld P,Zweegman S, Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. Haematologica. 2019 May;
[PubMed PMID: 30606791]
Level 1 (high-level) evidence
[3]
Chesi M,Nardini E,Lim RS,Smith KD,Kuehl WM,Bergsagel PL, The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998 Nov 1;
[PubMed PMID: 9787135]
[4]
Pasca S,Tomuleasa C,Teodorescu P,Ghiaur G,Dima D,Moisoiu V,Berce C,Stefan C,Ciechanover A,Einsele H, KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma. Frontiers in oncology. 2019;
[PubMed PMID: 31709194]
[5]
Dhodapkar MV, MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood. 2016 Dec 8
[PubMed PMID: 27737890]
[6]
Bumma N,Nagasaka M,Hemingway G,Miyashita H,Chowdhury T,Kim S,Vankayala HM,Ahmed S,Jasti P, Effect of Exposure to Agent Orange on the Risk of Monoclonal Gammopathy and Subsequent Transformation to Multiple Myeloma: A Single-Center Experience From the Veterans Affairs Hospital, Detroit. Clinical lymphoma, myeloma
[PubMed PMID: 32144026]
[7]
Mateos MV,Landgren O, MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology. Cancer treatment and research. 2016
[PubMed PMID: 27696254]
[8]
Waxman AJ,Mink PJ,Devesa SS,Anderson WF,Weiss BM,Kristinsson SY,McGlynn KA,Landgren O, Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010 Dec 16;
[PubMed PMID: 20823456]
[10]
Kyle RA,Larson DR,Therneau TM,Dispenzieri A,Kumar S,Cerhan JR,Rajkumar SV, Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. The New England journal of medicine. 2018 Jan 18;
[PubMed PMID: 29342381]
[11]
Weinhold N,Ashby C,Rasche L,Chavan SS,Stein C,Stephens OW,Tytarenko R,Bauer MA,Meissner T,Deshpande S,Patel PH,Buzder T,Molnar G,Peterson EA,van Rhee F,Zangari M,Thanendrarajan S,Schinke C,Tian E,Epstein J,Barlogie B,Davies FE,Heuck CJ,Walker BA,Morgan GJ, Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016 Sep 29;
[PubMed PMID: 27516441]
[12]
Hameed A,Brady JJ,Dowling P,Clynes M,O'Gorman P, Bone disease in multiple myeloma: pathophysiology and management. Cancer growth and metastasis. 2014;
[PubMed PMID: 25187738]
[13]
Kyle RA,Gertz MA,Witzig TE,Lust JA,Lacy MQ,Dispenzieri A,Fonseca R,Rajkumar SV,Offord JR,Larson DR,Plevak ME,Therneau TM,Greipp PR, Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic proceedings. 2003 Jan;
[PubMed PMID: 12528874]
[14]
Rajkumar SV, Updated Diagnostic Criteria and Staging System for Multiple Myeloma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2016
[PubMed PMID: 27249749]
[15]
Norris JR,Budil DE,Gast P,Chang CH,el-Kabbani O,Schiffer M, Correlation of paramagnetic states and molecular structure in bacterial photosynthetic reaction centers: the symmetry of the primary electron donor in Rhodopseudomonas viridis and Rhodobacter sphaeroides R-26. Proceedings of the National Academy of Sciences of the United States of America. 1989 Jun;
[PubMed PMID: 2543969]
[16]
Nishimura KK,Barlogie B,van Rhee F,Zangari M,Walker BA,Rosenthal A,Schinke C,Thanendrarajan S,Davies FE,Hoering A,Morgan GJ, Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood advances. 2020 Jan 28;
[PubMed PMID: 31990333]
Level 3 (low-level) evidence
[17]
Goldschmidt H,Lokhorst HM,Mai EK,van der Holt B,Blau IW,Zweegman S,Weisel KC,Vellenga E,Pfreundschuh M,Kersten MJ,Scheid C,Croockewit S,Raymakers R,Hose D,Potamianou A,Jauch A,Hillengass J,Stevens-Kroef M,Raab MS,Broijl A,Lindemann HW,Bos GMJ,Brossart P,van Marwijk Kooy M,Ypma P,Duehrsen U,Schaafsma RM,Bertsch U,Hielscher T,Jarari L,Salwender HJ,Sonneveld P, Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia. 2018 Feb;
[PubMed PMID: 28761118]
[18]
Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Wang J, Van Rampelbergh R, Uhlar CM, Tromp B, Delioukina M, Vermeulen J, Usmani SZ. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. The Lancet. Oncology. 2021 Nov:22(11):1582-1596. doi: 10.1016/S1470-2045(21)00466-6. Epub 2021 Oct 13
[PubMed PMID: 34655533]
Level 1 (high-level) evidence
[19]
Mateos MV,San Miguel JF, Management of multiple myeloma in the newly diagnosed patient. Hematology. American Society of Hematology. Education Program. 2017 Dec 8
[PubMed PMID: 29222298]
[20]
Kumar SK,Mikhael JR,Buadi FK,Dingli D,Dispenzieri A,Fonseca R,Gertz MA,Greipp PR,Hayman SR,Kyle RA,Lacy MQ,Lust JA,Reeder CB,Roy V,Russell SJ,Short KE,Stewart AK,Witzig TE,Zeldenrust SR,Dalton RJ,Rajkumar SV,Bergsagel PL, Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clinic proceedings. 2009 Dec;
[PubMed PMID: 19955246]
Level 3 (low-level) evidence
[21]
Vogelsberg A,Schürch CM,Fend F, [Multiple myeloma from the pathologist's perspective]. Der Radiologe. 2022 Jan;
[PubMed PMID: 34661686]
Level 3 (low-level) evidence
[22]
Lussier T,Schoebe N,Mai S, Risk Stratification and Treatment in Smoldering Multiple Myeloma. Cells. 2021 Dec 31;
[PubMed PMID: 35011692]
[23]
Lasocki A,Seymour JF, Central nervous system manifestations of systemic haematological malignancies and key differentials. Clinical radiology. 2022 Feb 12;
[PubMed PMID: 35164931]
[24]
Tazoe K,Takakuwa T,Makuuchi Y,Kuno M,Harada N,Okamura H,Nishimoto M,Koh H,Nakashima Y,Nakamae H,Hino M, [AL amyloidosis presenting with fluminant multiorgan failure accompanied by rapid progression from MGUS to multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2022;
[PubMed PMID: 35135949]
[25]
Durie BG, The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. European journal of cancer (Oxford, England : 1990). 2006 Jul
[PubMed PMID: 16777405]
[26]
Palumbo A,Avet-Loiseau H,Oliva S,Lokhorst HM,Goldschmidt H,Rosinol L,Richardson P,Caltagirone S,Lahuerta JJ,Facon T,Bringhen S,Gay F,Attal M,Passera R,Spencer A,Offidani M,Kumar S,Musto P,Lonial S,Petrucci MT,Orlowski RZ,Zamagni E,Morgan G,Dimopoulos MA,Durie BG,Anderson KC,Sonneveld P,San Miguel J,Cavo M,Rajkumar SV,Moreau P, Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Sep 10
[PubMed PMID: 26240224]
[27]
Goldman-Mazur S,Jurczyszyn A,Castillo JJ,Waszczuk-Gajda A,Grząśko N,Radocha J,Bittrich M,Kortüm KM,Gozzetti A,Usnarska-Zubkiewicz L,Davila Valls J,Jayabalan DS,Niesvizky R,Kelman J,Coriu D,Rosiñol L,Szukalski Ł,González-Calle V,Mateos MV,Jamroziak K,Hus I,Avivi I,Cohen Y,Suska A,Chappell A,Madduri D,Chhabra S,Kleman A,Hari P,Delforge M,Robak P,Gentile M,Kozłowska I,Goldberg SL,Czepiel J,Silbermann R,Olszewski AJ,Barth P,Mikala G,Chim CS,Długosz-Danecka M,Grosicki S,Vesole DH, A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. American journal of hematology. 2020 May;
[PubMed PMID: 32072687]
Level 2 (mid-level) evidence
[28]
Corre J,Perrot A,Caillot D,Belhadj K,Hulin C,Leleu X,Mohty M,Facon T,Buisson L,Do Souto L,Lannes R,Dufrechou S,Prade N,Orsini-Piocelle F,Voillat L,Jaccard A,Karlin L,Macro M,Brechignac S,Dib M,Sanhes L,Fontan J,Clement-Filliatre L,Marolleau JP,Minvielle S,Moreau P,Avet-Loiseau H, del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. Blood. 2021 Mar 4;
[PubMed PMID: 33080624]
[29]
Terpos E,Kleber M,Engelhardt M,Zweegman S,Gay F,Kastritis E,van de Donk NW,Bruno B,Sezer O,Broijl A,Bringhen S,Beksac M,Larocca A,Hajek R,Musto P,Johnsen HE,Morabito F,Ludwig H,Cavo M,Einsele H,Sonneveld P,Dimopoulos MA,Palumbo A, European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015 Oct
[PubMed PMID: 26432383]
[30]
Mohty B,El-Cheikh J,Yakoub-Agha I,Moreau P,Harousseau JL,Mohty M, Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica. 2010 Feb;
[PubMed PMID: 20139393]
[31]
Kristinsson SY, Thrombosis in multiple myeloma. Hematology. American Society of Hematology. Education Program. 2010;
[PubMed PMID: 21239832]
[32]
Marinac CR,Ghobrial IM,Birmann BM,Soiffer J,Rebbeck TR, Dissecting racial disparities in multiple myeloma. Blood cancer journal. 2020 Feb 17;
[PubMed PMID: 32066732]
[33]
Herget GW,Kälberer F,Ihorst G,Graziani G,Klein L,Rassner M,Gehler C,Jung J,Schmal H,Wäsch R,Engelhardt M, Interdisciplinary approach to multiple myeloma - time to diagnosis and warning signs. Leukemia & lymphoma. 2021 Apr
[PubMed PMID: 33225781]
[34]
Raje NS,Yee AJ,Roodman GD, Advances in supportive care for multiple myeloma. Journal of the National Comprehensive Cancer Network : JNCCN. 2014 Apr
[PubMed PMID: 24717569]
Level 3 (low-level) evidence
[36]
Ghabashi EH,Sharaf BM,Kalaktawi WA,Calacattawi R,Calacattawi AW, The Magnitude and Effects of Early Integration of Palliative Care Into Oncology Service Among Adult Advanced Cancer Patients at a Tertiary Care Hospital. Cureus. 2021 May 29;
[PubMed PMID: 34211813]
[37]
Freeman AT,Kuo M,Zhou L,Trogdon JG,Baggett CD,Tuchman SA,Shea TC,Wood WA, Influence of Treating Facility, Provider Volume, and Patient-Sharing on Survival of Patients With Multiple Myeloma. Journal of the National Comprehensive Cancer Network : JNCCN. 2019 Sep 1;
[PubMed PMID: 31487686]